Barclays Cuts Estimates on Par Pharmaceutical (PRX); Removing Lovaza Contribution From Model

May 31, 2012 2:11 PM EDT Send to a Friend
Get Alerts PRX Hot Sheet
Price: $49.98 --0%

Rating Summary:
    2 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 14 | New: 52
Trade PRX Now!
Join SI Premium – FREE
Barclays maintains an 'Equalweight' on Par Pharmaceutical (NYSE: PRX) price target of $35.00.

Analyst, Douglas D. Tsao, said, "We our removing a generic Lovaza contribution from our 2012-2016 estimates and now assume no contribution until patent expiry in 2017. Our revised EPS estimates are as follows: 2012 - $3.70 vs previous $3.85; 2013 - $2.92 vs previous $3.26; 2014 - $3.29 vs previous $4.24; 2015 - $3.46 vs previous $3.91; 2016 - $4.80 vs previous $5.25."

For an analyst ratings summary and ratings history on Par Pharmaceutical click here. For more ratings news on Par Pharmaceutical click here.

Shares of Par Pharmaceutical closed at $37.01 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Barclays

Add Your Comment